Published in Glycobiology on July 31, 2006
Glycosylation in cancer: mechanisms and clinical implications. Nat Rev Cancer (2015) 2.00
New discoveries on the biology and detection of human chorionic gonadotropin. Reprod Biol Endocrinol (2009) 1.38
Human urinary glycoproteomics; attachment site specific analysis of N- and O-linked glycosylations by CID and ECD. Mol Cell Proteomics (2011) 1.23
Biological functions of hCG and hCG-related molecules. Reprod Biol Endocrinol (2010) 1.23
Carbohydrates and activity of natural and recombinant tissue factor. J Biol Chem (2009) 1.13
Quantitative liquid chromatography-mass spectrometry-multiple reaction monitoring (LC-MS-MRM) analysis of site-specific glycoforms of haptoglobin in liver disease. Mol Cell Proteomics (2013) 1.11
HCG variants, the growth factors which drive human malignancies. Am J Cancer Res (2011) 1.05
Engineering of N. benthamiana L. plants for production of N-acetylgalactosamine-glycosylated proteins--towards development of a plant-based platform for production of protein therapeutics with mucin type O-glycosylation. BMC Biotechnol (2010) 0.90
The sweet and sour of serological glycoprotein tumor biomarker quantification. BMC Med (2013) 0.88
Gonadotropins in doping: pharmacological basis and detection of illicit use. Br J Pharmacol (2008) 0.88
Investigations with O-linked protein glycosylations by matrix-assisted laser desorption/ionization Fourier transform ion cyclotron resonance mass spectrometry. J Mass Spectrom (2008) 0.86
Extragonadal actions of chorionic gonadotropin. Rev Endocr Metab Disord (2011) 0.84
The sensitivity and specificity of hyperglycosylated hCG (hhCG) levels to reliably diagnose clinical IVF pregnancies at 6 days following embryo transfer. J Assist Reprod Genet (2012) 0.84
Synthesis and secretion of gonadotropins including structure-function correlates. Rev Endocr Metab Disord (2011) 0.83
Glycoprotein disease markers and single protein-omics. Mol Cell Proteomics (2013) 0.83
Chemical synthesis of the β-subunit of human luteinizing (hLH) and chorionic gonadotropin (hCG) glycoprotein hormones. J Am Chem Soc (2014) 0.79
Total synthesis of glycosylated proteins. Top Curr Chem (2015) 0.78
Mammalian sialyltransferase ST3Gal-II: its exchange sialylation catalytic properties allow labeling of sialyl residues in mucin-type sialylated glycoproteins and specific gangliosides. Biochemistry (2011) 0.78
Candidate epitopes for measurement of hCG and related molecules: the second ISOBM TD-7 workshop. Tumour Biol (2013) 0.77
Glycosylation-Based Serum Biomarkers for Cancer Diagnostics and Prognostics. Biomed Res Int (2015) 0.77
Recognition of N-glycoforms in human chorionic gonadotropin by monoclonal antibodies and their interaction motifs. J Biol Chem (2015) 0.75
Management of nonpregnant women with elevated human chorionic gonadotropin. Case Rep Obstet Gynecol (2013) 0.75
Human Chorionic Gonadotropin and Breast Cancer. Int J Mol Sci (2017) 0.75
Prostate specific antigen for early detection of prostate cancer: longitudinal study. BMJ (2009) 3.00
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. Eur Urol (2007) 2.42
Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol (2007) 2.09
Negative interference in cardiac troponin I immunoassays from a frequently occurring serum and plasma component. Clin Chem (2003) 1.97
Hypothermia-treated cardiac arrest patients with good neurological outcome differ early in quantitative variables of EEG suppression and epileptiform activity. Crit Care Med (2009) 1.93
Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer (2011) 1.86
Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. Clin Chem (2009) 1.82
Prevention of bone loss after allogeneic stem cell transplantation by calcium, vitamin D, and sex hormone replacement with or without pamidronate. J Clin Endocrinol Metab (2005) 1.62
A nationwide survey of mortality in acromegaly. J Clin Endocrinol Metab (2005) 1.51
Specific immunoassay reveals increased serum trypsinogen 3 in acute pancreatitis. Clin Chem (2011) 1.44
Prognostic significance of tumor-associated trypsin inhibitor (TATI) and human chorionic gonadotropin-β (hCGβ) in patients with hepatocellular carcinoma. Scand J Gastroenterol (2013) 1.44
High levels of circulating insulin-like growth factor-I increase prostate cancer risk: a prospective study in a population-based nonscreened cohort. J Clin Oncol (2004) 1.41
Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer (2010) 1.41
Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res (2010) 1.33
Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer. Cancer Res (2002) 1.28
Human chorionic gonadotropin in cancer. Clin Biochem (2004) 1.27
The classification, functions and clinical use of different isoforms of HCG. Hum Reprod Update (2006) 1.26
Lead-time in prostate cancer screening (Finland). Cancer Causes Control (2002) 1.25
DNA damage recognition via activated ATM and p53 pathway in nonproliferating human prostate tissue. Cancer Res (2010) 1.24
Risk factors for clinical stress fractures in male military recruits: a prospective cohort study. Bone (2005) 1.22
Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem (2003) 1.18
Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17
Vitamin D status as a determinant of peak bone mass in young Finnish men. J Clin Endocrinol Metab (2004) 1.14
High levels of circulating testosterone are not associated with increased prostate cancer risk: a pooled prospective study. Int J Cancer (2004) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Sensitive protein detection via triple-binder proximity ligation assays. Nat Methods (2006) 1.11
Monitoring of seminoma patients with serum markers. Cancer (2013) 1.10
Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer (2002) 1.09
Determination of 25-hydroxyvitamin D in serum by HPLC and immunoassay. Clin Chem (2003) 1.08
The impact of interscreening interval and age on prostate cancer screening with prostate-specific antigen. Eur Urol (2012) 1.08
Increased activity of the hypothalamic-pituitary-testicular axis in infancy results in increased androgen action in premature boys. J Clin Endocrinol Metab (2010) 1.08
Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology (2004) 1.06
Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry (2003) 1.04
Preparation and characterization of new WHO reference reagents for human chorionic gonadotropin and metabolites. Clin Chem (2003) 1.03
Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab (2005) 1.02
CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol (2005) 1.01
Prostate cancer mortality in the Finnish randomized screening trial. J Natl Cancer Inst (2013) 1.01
Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol (2002) 1.01
Plasma leptin is not associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.01
Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. Prostate (2008) 0.99
Placental 11 beta-hydroxysteroid dehydrogenase-2 and fetal cortisol/cortisone shuttle in small preterm infants. J Clin Endocrinol Metab (2003) 0.98
Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue. Prostate (2005) 0.96
Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res (2004) 0.95
Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor. Crit Rev Clin Lab Sci (2006) 0.95
Maternal serum angiopoietin-1 and -2 and tie-2 in early pregnancy ending in preeclampsia or intrauterine growth retardation. J Clin Endocrinol Metab (2009) 0.93
The proportion of free PSA and upgrading of biopsy Gleason score after radical prostatectomy. Urol Int (2010) 0.93
Rye whole grain and bran intake compared with refined wheat decreases urinary C-peptide, plasma insulin, and prostate specific antigen in men with prostate cancer. J Nutr (2010) 0.93
Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab (2006) 0.93
Tumor-associated trypsin inhibitor as a prognostic factor during follow-up of bladder cancer. Urology (2003) 0.92
Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int J Cancer (2012) 0.92
Expression of tumor-associated trypsinogens (TAT-1 and TAT-2) in prostate cancer. Prostate (2005) 0.91
KLF6 IVS1 -27G>A variant and the risk of prostate cancer in Finland. Eur Urol (2006) 0.91
Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients. BMC Cancer (2010) 0.91
Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol (2002) 0.91
Determination of aldosterone in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.90
Pancreatic secretory trypsin inhibitor (SPINK1) gene mutations in patients with acute pancreatitis. Pancreas (2005) 0.90
Fecal calprotectin and S100A12 have low utility in prediction of small bowel Crohn's disease detected by wireless capsule endoscopy. Scand J Gastroenterol (2012) 0.90
Differences in total human chorionic gonadotropin immunoassay analytical specificity and ability to measure human chorionic gonadotropin in gestational trophoblastic disease and germ cell tumors. J Reprod Med (2010) 0.89
Determination of human chorionic gonadotropin. Best Pract Res Clin Endocrinol Metab (2013) 0.89
Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res (2006) 0.89
Intact HCG, free HCG beta subunit and HCG beta core fragment: longitudinal patterns in urine during early pregnancy. Hum Reprod (2005) 0.89
SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. Int J Cancer (2007) 0.89
False-negative results in point-of-care qualitative human chorionic gonadotropin (hCG) devices due to excess hCGbeta core fragment. Clin Chem (2009) 0.88
Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. J Gene Med (2007) 0.88
Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor. Clin Chem (2009) 0.88
Treatment of prostate cancer with Ad5/3Delta24hCG allows non-invasive detection of the magnitude and persistence of virus replication in vivo. Mol Cancer Ther (2007) 0.88
Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate (2002) 0.88
Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma. World J Gastroenterol (2005) 0.88
Monoclonal antibodies, immunofluorometric assay, and detection of human semenogelin in male reproductive tract: no association with in vitro fertilizing capacity of sperm. Biol Reprod (2002) 0.88
Preanalytical factors and reference intervals for serum hepcidin LC-MS/MS method. Clin Chim Acta (2011) 0.87
Technique for strand-specific gene-expression analysis and monitoring of primer-independent cDNA synthesis in reverse transcription. Biotechniques (2012) 0.87
Urinary matrix metalloproteinase -8, -9, -14 and their regulators (TRY-1, TRY-2, TATI) in patients with diabetic nephropathy. Ann Med (2008) 0.87
Intracellular co-localization of trypsin-2 and matrix metalloprotease-9: possible proteolytic cascade of trypsin-2, MMP-9 and enterokinase in carcinoma. Exp Cell Res (2007) 0.87
Urinary epidermal growth factor and interleukin-6 levels in patients with painful bladder syndrome/interstitial cystitis treated with cyclosporine or pentosan polysulfate sodium. Urology (2008) 0.86
Combination of HCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res (2002) 0.86
Activity and stability of human kallikrein-2-specific linear and cyclic peptide inhibitors. J Pept Sci (2007) 0.86
Development of peptides specifically modulating the activity of KLK2 and KLK3. Biol Chem (2008) 0.86
Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy. Lung Cancer (2003) 0.85